IWF’s latest updates to the TCRR - IWF
4 weeks ago • Google News
Tcr2 Therapeutics Inc (TCRR)
US$ 1.48-5.73%
Price Chart
Key Statistics
Market Cap
$ 58.11M
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
3.88M
52W High
$ 0.00
52W Low
$ 0.00
Dividend Yield
0.00%
Beta
1.93
Technicals
50-Day MA
1.6899
200-Day MA
1.5592
52 Week High
N/A
52 Week Low
N/A
About TCRR
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.
Employees
58
Headquarters
Cambridge, MA
CEO
Dr. Garry E. Menzel M.B.A., Ph.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg